FCGR3A人重组蛋白

蛋白名称:FCGR3A人重组蛋白，10389-H08H

蛋白构建:A DNA sequence encoding the extracellular domain (Met 1-Gln 208) of human CD16a (P08637-1) precursor was expressed with a C-terminal polyhistidine tag.

表达宿主:HEK293 Cells

蛋白纯度:≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC. ≥ 90 % as determined by SEC-MALS(Routinely tested).

蛋白活性:

1.Loaded Human FcγRIIIA / CD16a (F176) recombinant protein (Cat. 10389-H08H ) on His1K Biosensor, can bind Bevacizumab (IgG1) with an affinity constant of 1.9 μM as determined in a BLI assay (Sartorius Octet Red384) (Routinely tested).

2.Captured Bevacizumab (IgG1) on proA Chip can bind Human FcγRIIIA / CD16a (F176) recombinant protein (Cat. 10389-H08H ) with an affinity constant of 2.67 µM as determined in an SPR assay (Biacore T200) (Routinely tested).

3.Recombinant Human CD16a/FCGR3A/Fc gamma RIIIA Protein (176F), His Tag (Cat. No. 10389-H08H) captured on CM5 Chip via Anti-his antibody chip, can bind Rituximab derived Anti-CD20 antibody, Human IgG1 with an affinity constant of 0.499 µM as determined in an SPR assay (Biacore T200) (QC tested).

蛋白内毒素:< 1.0 EU per μg of the protein as determined by the LAL method

预测N端:Gly 17

蛋白分子量:The secreted recombinant human CD16a consists of 203 amino acids and has a predicted molecular mass of 23.3 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of human CD16a is approximately 45.2 kDa due to glycosylation. The molecular weight of this protein is around 36-48 kDa verified by SEC-MALS (Routinely tested).

蛋白NP号:P08637-1

蛋白氨基酸序列:Met1-Gln208,176F

蛋白标签:C-His

欢迎去义翘神州网查看FCGR3A人重组蛋白，10389-H08H详细信息。网址：https://cn.sinobiological.com/recombinant-proteins/human-cd16a-10389-h08h

义翘神州研发团队拥有多年的重组蛋白研发经验。多年来，我们的团队已开发出超过9300余种重组蛋白，涵盖免疫检查点、抗体药物靶点、CAR-T细胞治疗靶点、Fc受体、流感病毒蛋白以及细胞因子等热门研究领域。义翘神州重组蛋白具有高纯度、高生物活性和低内毒素水平等特性，可为生物药靶点发现、蛋白质结构和功能分析、细胞疗法和重组酶酶学性质等科学研究提供支持。

义翘神州利用蛋白表达平台，提供重组蛋白生产"一站式"技术服务。我们的服务包括蛋白基因合成、蛋白质密码子优化、蛋白质表达载体设计、大规模细胞培养和发酵、蛋白纯化和蛋白质量控制检测。我们在蛋白表达和大规模生产方面有着显著的成本节约和速度优势，同时在设计各种类型的重组蛋白纯化项目（带或不带纯化标签）方面也拥有着丰富的经验和专业技术。 义翘神州拥有经验丰富的技术团队，每年可研发生产1,000+种重组蛋白开发和大规模生产项目。我们有能力进行快速的蛋白质表达和纯化工艺开发，根据需求进行工艺放大研究，并且可满足高通量和大规模批量生产蛋白质的要求。 我们致力于成为重组蛋白和单克隆抗体大规模生产的实验室，为药物研发企业和生命科学机构提供高水平的技术服务。

欢迎小伙伴来咨询哦!  请注明来源、姓名，单位！

关注义翘神州或添加微信“sinobio2023"进行联系！